Hjem › Overvekt › Ohio › Cincinnati
Kliniske studier for Overvekt i Cincinnati, OH
14 studier for Overvekt søker deltakere på steder i og rundt Cincinnati (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
RekruttererFase 2
- CTI Clinical Research Center /ID# 282043, Cincinnati
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
RekruttererFase 3
- Midwest Eye Center, Cincinnati
- Velocity Clinical Research, Mt. Auburn, Cincinnati
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
RekruttererFase 3
- CTI Clinical Research Center, Cincinnati
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
RekruttererFase 3
- CTI Clinical Research Center, Cincinnati
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
RekruttererFase 3
- Velocity Clinical Research - Auburn, Cincinnati
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
RekruttererFase 2
- CTI Clinical Research Center, Cincinnati
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
RekruttererFase 3
- AURORA-1 Clinical Site, Cincinnati
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
RekruttererFase 3
- AURORA-2 Clinical Site, Cincinnati
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
RekruttererFase 3
- CTI Clinical Research Center, Cincinnati
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
RekruttererFase 3
- CTI Clinical Research Center, Cincinnati
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RekruttererFase 2
- CTI Clinical Research Center, Cincinnati
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
RekruttererFase 3
- Clinical Trial Investigator Clinical Research Center, Cincinnati
- Velocity Clinical Research - Cincinnati, Cincinnati
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
RekruttererFase 3
- Velocity Clinical Research - Cincinnati, Cincinnati
- Velocity Clinical Research - Springdale, Cincinnati
Effects of Exercise on Lipids and Endothelial Function in Youth
Rekrutterer
- Cincinnati Children's Hospital Medical Center, Cincinnati
Overvekt-studier i andre byer
- San Antonio, TX34 studier
- Houston, TX33 studier
- Chicago, IL28 studier
- Orlando, FL27 studier
- Las Vegas, NV23 studier
- Miami, FL23 studier
- Atlanta, GA20 studier
- Dallas, TX20 studier
- New York City, NY19 studier
- Jacksonville, FL19 studier
- Washington, DC19 studier
- Austin, TX18 studier
Andre studier i Cincinnati
- Ikke-småcellet lungekreft35 studier
- Kreft (alle typer)27 studier
- Brystkreft25 studier
- Hjertesvikt24 studier
- Kolorektal kreft21 studier
- Akut myelogen leukemi20 studier
- Metastatisk kreft20 studier
- Eggstokkreft19 studier
- Lungekreft19 studier
- Fedme19 studier
- Prostatakreft18 studier
- Multipelt myelom17 studier
Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.